Document is current
Any future updates will be listed below
-
Authors
Habtemariam, Henok D. https://orcid.org/0000-0003-1542-7616
Guchelaar, Henk-Jan https://orcid.org/0000-0002-7085-1383
Manson, Lisanne E. N.
Swen, Jesse J.
Kant, Agnes C.
Böhringer, Stefan
-
Funding
Funding for this research was provided by:
Horizon 2020 Framework Programme (668353)
- License Information
-
More Information
Article History
Accepted: 23 May 2025
First Online: 14 June 2025
Declarations
:
: The PREPARE study was funded by the EU Horizon 2020 Programme (grant agreement number 668353 [U-PGx]).
: Henok D. Habtemariam, Henk-Jan Guchelaar, Lisanne E.N. Manson, Jesse J. Swen, Agnes C. Kant, and Stefan Böhringer have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this article. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
: The data were collected as part of the PREPARE study and ethical approval was therefore provided by the Leiden University Medical Center and other participating centers of the prior study. Ethical approval was granted by the Leiden University Medical Center Institutional Review Board and the Medical Ethics Review Committee (P16.298).
: Informed consent, including consent to participate, was given by participants as part of the PREPARE study. This analysis was based on data provisioning by the PREPARE study according to the data-sharing rules of the project.
: Consent for publication was given by participants as part of the PREPARE study.
: Data from the PREPARE study are not publicly available but are planned to be made available after preplanned analyses have been completed. A complete deidentified dataset will be made accessible, together with a data dictionary, for a minimum of 5 years. Requests for access to the data can be made by sending an e-mail together with a research plan to the corresponding author and will be evaluated by and require authorization from the Ubiquitous Pharmacogenomics Consortium executive board. The criteria for data access (e.g., who will be granted access, for what types of analyses, and by what mechanism) have yet to be determined; the procedure is under development by the consortium’s executive board and will be published separately.
: The code will be provided upon request.
: HDH, H-JG, and SB were involved in the conception, design, analysis of the data, and drafting of the article. All the authors were involved in revising the article and all authors read and approved the final version.
